Free tool
FAERS Monitor: Paricalcitol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205917 or its brand name (Paricalcitol, Paricalcitol). Reports on generic versions are filed under their own applications.
Reports
1,024
Serious
842
82% of reports
Hospitalization
406
Death reported
204
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- calciphylaxis66
- death66
- chronic kidney disease57
- renal failure56
- pneumonia54
- drug ineffective45
- nausea45
- sepsis41
- dyspnoea40
- end stage renal disease38
- acute kidney injury37
- renal impairment37
- hypocalcaemia35
- pain35
- asthenia33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 9 |
| 2006 | 8 |
| 2007 | 10 |
| 2008 | 16 |
| 2009 | 13 |
| 2010 | 16 |
| 2011 | 31 |
| 2012 | 29 |
| 2013 | 21 |
| 2014 | 52 |
| 2015 | 57 |
| 2016 | 94 |
| 2017 | 110 |
| 2018 | 127 |
| 2019 | 109 |
| 2020 | 101 |
| 2021 | 48 |
| 2022 | 39 |
| 2023 | 52 |
| 2024 | 24 |
| 2025 | 21 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| calciphylaxisSignal | 66 | 766.6 | 604.3 | 47,921 |
| end stage renal diseaseSignal | 38 | 42.9 | 31.4 | 1,511 |
| hypocalcaemiaSignal | 35 | 38.0 | 27.5 | 1,225 |
| chronic kidney diseaseSignal | 57 | 15.4 | 12.0 | 756 |
| renal impairmentSignal | 37 | 9.1 | 6.6 | 258 |
| renal failureSignal | 56 | 8.7 | 6.7 | 374 |
| sepsisSignal | 41 | 7.6 | 5.6 | 228 |
| acute kidney injurySignal | 37 | 5.0 | 3.6 | 114 |
| pneumoniaSignal | 54 | 3.4 | 2.6 | 92 |
| asthenia | 33 | 1.8 | 1.3 | 11 |
| death | 66 | 1.6 | 1.2 | 14 |
| dyspnoea | 40 | 1.5 | 1.1 | 5 |
| pain | 35 | 1.2 | 0.8 | 1 |
| nausea | 45 | 1.2 | 0.9 | 1 |
| drug ineffective | 45 | 0.7 | 0.5 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.